Avoro Capital Advisors LLC Has $375.94 Million Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Avoro Capital Advisors LLC lifted its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 2.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,900,000 shares of the biotechnology company’s stock after acquiring an additional 300,000 shares during the period. Arrowhead Pharmaceuticals accounts for 4.9% of Avoro Capital Advisors LLC’s portfolio, making the stock its 6th largest position. Avoro Capital Advisors LLC owned 7.88% of Arrowhead Pharmaceuticals worth $375,941,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Royal Bank of Canada grew its holdings in Arrowhead Pharmaceuticals by 30.2% during the first quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company’s stock worth $576,000 after acquiring an additional 10,496 shares during the period. AQR Capital Management LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the first quarter valued at about $514,000. Goldman Sachs Group Inc. boosted its holdings in Arrowhead Pharmaceuticals by 34.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after buying an additional 447,456 shares during the last quarter. Empowered Funds LLC increased its stake in Arrowhead Pharmaceuticals by 6.9% during the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock worth $194,000 after buying an additional 979 shares in the last quarter. Finally, Focus Partners Wealth raised its holdings in shares of Arrowhead Pharmaceuticals by 1,339.5% during the first quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company’s stock valued at $207,000 after acquiring an additional 15,123 shares during the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Chardan Capital boosted their price target on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. B. Riley Financial lifted their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. The Goldman Sachs Group upped their price target on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, January 7th. Weiss Ratings raised Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, February 6th. Finally, Bank of America lifted their price target on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $81.67.

Insider Activity at Arrowhead Pharmaceuticals

In related news, Director Victoria Vakiener sold 10,040 shares of Arrowhead Pharmaceuticals stock in a transaction on Friday, December 19th. The shares were sold at an average price of $67.68, for a total transaction of $679,507.20. Following the sale, the director directly owned 35,723 shares in the company, valued at $2,417,732.64. This trade represents a 21.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Patrick O’brien sold 49,493 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $63.11, for a total transaction of $3,123,503.23. Following the completion of the transaction, the chief operating officer owned 474,908 shares of the company’s stock, valued at $29,971,443.88. This represents a 9.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 495,836 shares of company stock valued at $32,759,810. Corporate insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Stock Up 0.1%

Arrowhead Pharmaceuticals stock opened at $55.05 on Friday. The stock has a market cap of $7.71 billion, a PE ratio of 35.98 and a beta of 1.23. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.38 and a quick ratio of 3.38. The stock’s fifty day moving average is $64.47 and its two-hundred day moving average is $51.15. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The business had revenue of $264.03 million during the quarter, compared to analysts’ expectations of $225.66 million. During the same quarter in the previous year, the company posted ($1.39) EPS. The company’s revenue was up 10461.3% compared to the same quarter last year. On average, sell-side analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.